Teva Pharmaceutical Industries. has filed a patent for a fixed-dose dry powder inhalation formulation containing fluticasone propionate and albuterol sulfate with an a-lactose monohydrate carrier. The formulation aims to stabilize fluticasone propionate with albuterol sulfate. GlobalData’s report on Teva Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Teva Pharmaceutical Industries, Cancer treatment biomarkers was a key innovation area identified from patents. Teva Pharmaceutical Industries's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Dry powder inhalation formulation with fluticasone and albuterol

Source: United States Patent and Trademark Office (USPTO). Credit: Teva Pharmaceutical Industries Ltd

A newly filed patent (Publication Number: US20240033222A1) discloses a dry powder inhalable formulation designed for the treatment of asthma or COPD. The formulation includes fluticasone propionate, albuterol sulfate, and a-lactose monohydrate, with specific particle size distributions for each component. The weight ratio of albuterol sulfate to fluticasone propionate is defined, and the formulation does not include a ternary excipient. The patent also covers a method for treating asthma or COPD using the inhalable formulation, with specific dosage limits for fluticasone propionate and albuterol sulfate.

Furthermore, the patent details a process for preparing the dry powder inhalable formulation, involving specific steps for mixing the components and conditioning the mixture. The process includes exposure to specific temperature and humidity conditions for a defined duration. Additionally, the patent covers the design of a dry powder inhaler with a cyclone deagglomerator for breaking up agglomerates of the dry powder, ensuring efficient delivery of the inhalable formulation. The inhaler design includes specific features such as swirl chambers, vanes, and sealing surfaces to optimize the delivery of the formulation to the patient.

To know more about GlobalData’s detailed insights on Teva Pharmaceutical Industries, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies